LJ, C., TW, L., H, T., P, S., SM, J., F, V., . . . M, D. (2025). An Updated Indirect Comparison of Elranatamab Versus a Real-World External Control Arm in Triple-Class Refractory Multiple Myeloma. Dove Medical Press.
Chicago Style (17th ed.) CitationLJ, Costa, et al. An Updated Indirect Comparison of Elranatamab Versus a Real-World External Control Arm in Triple-Class Refractory Multiple Myeloma. Dove Medical Press, 2025.
MLA (9th ed.) CitationLJ, Costa, et al. An Updated Indirect Comparison of Elranatamab Versus a Real-World External Control Arm in Triple-Class Refractory Multiple Myeloma. Dove Medical Press, 2025.
Warning: These citations may not always be 100% accurate.